top of page

USFDA MD Guidance: Transition Plan for M.D Issued Emergency Use Authorizations Related to COVID-19

Writer's picture: Sharan MuruganSharan Murugan

Emergency Use Authorization (EUA) is a mechanism that allows the US Food and Drug Administration (FDA) to authorize the use of medical products during public health emergencies, such as the COVID-19 pandemic.

The FDA acknowledges that having to adjust from COVID-19 pandemic policies to "normal operations" will take some time for manufacturers, distributors, healthcare facilities, healthcare providers, patients, and consumers.


In order to provide a clear policy to all stakeholders and FDA staff, FDA is issuing this guidance. The FDA provides general recommendations for this transition process regarding devices issued emergency use authorizations (EUAs) related to COVID-19, as well as recommendations regarding the submission of a marketing submission, as applicable, and other actions.


During the COVID-19 public health emergency (PHE), FDA issued a companion transition guidance that explains FDA's recommendations for devices falling within certain enforcement policies. FD&C Act and its implementing regulations require manufacturers and other stakeholders to comply with certain transition guidance in order to prepare for a smooth transition to normal operation.



Comentarios


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page